Research reveals CST4 enhances tumor aggressiveness in ovarian cancer, suggesting it as a potential drug target.
CST4 is a novel oncogenic regulator in OC that promotes EMT and tumor aggressiveness via the Wnt/β-catenin signaling pathway. It may serve as an independent prognostic biomarker and potential therapeutic target for OC.
No takes yet. Share an insight, caveat, or question.
Shao et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: